Diligent Investors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $679K | Buy |
2,700
+63
| +2% | +$13.6K | 0.15% | 181 |
|
|
2026
Q1 | $574K | Buy |
2,637
+62
| +2% | +$13.8K | 0.14% | 182 |
|
|
2025
Q4 | $588K | Buy |
2,575
+18
| +0.7% | +$4.1K | 0.14% | 176 |
|
|
2025
Q3 | $592K | Sell |
2,557
-5,857
| -70% | -$1.19M | 0.15% | 169 |
|
|
2025
Q2 | $1.56M | Buy |
8,414
+9
| +0.1% | +$1.67K | 0.37% | 74 |
|
|
2025
Q1 | $1.76M | Sell |
8,405
-216
| -3% | -$42K | 0.43% | 55 |
|
|
2024
Q4 | $1.53M | Buy |
8,621
+21
| +0.2% | +$3.86K | 0.35% | 72 |
|
|
2024
Q3 | $1.7M | Buy |
8,600
+10
| +0.1% | +$1.87K | 0.39% | 65 |
|
|
2024
Q2 | $1.47M | Buy |
8,590
+16
| +0.2% | +$2.65K | 0.36% | 76 |
|
|
2024
Q1 | $1.56M | Buy |
8,574
+4
| +0% | +$689 | 0.39% | 68 |
|
|
2023
Q4 | $1.33M | Buy |
8,570
+13
| +0.2% | +$1.9K | 0.36% | 75 |
|
|
2023
Q3 | $1.28M | Sell |
8,557
-189
| -2% | -$27.7K | 0.39% | 68 |
|
|
2023
Q2 | $1.18M | Buy |
8,746
+12
| +0.1% | +$1.76K | 0.35% | 72 |
|
|
2023
Q1 | $1.39M | Buy |
8,734
+11
| +0.1% | +$1.68K | 0.43% | 52 |
|
|
2022
Q4 | $1.41M | Sell |
8,723
-17
| -0.2% | -$2.61K | 0.46% | 49 |
|
|
2022
Q3 | $1.17M | Sell |
8,740
-101
| -1% | -$14.5K | 0.42% | 57 |
|
|
2022
Q2 | $1.35M | Buy |
8,841
+10
| +0.1% | +$1.53K | 0.46% | 50 |
|
|
2022
Q1 | $1.43M | Sell |
8,831
-245
| -3% | -$35.6K | 0.42% | 54 |
|
|
2021
Q4 | $1.23M | Sell |
9,076
-20
| -0.2% | -$2.36K | 0.34% | 68 |
|
|
2021
Q3 | $1.02M | Hold |
9,096
| – | – | 0.35% | 71 |
|
|
2021
Q2 | $1.02M | Sell |
9,096
-516
| -5% | -$58.1K | 0.35% | 71 |
|
|
2021
Q1 | $1.04M | Buy |
9,612
+588
| +7% | +$62.9K | 0.38% | 66 |
|
|
2020
Q4 | $967K | Sell |
9,024
-3
| -0% | -$288 | 0.39% | 68 |
|
|
2020
Q3 | $791K | Buy |
9,027
+86
| +1% | +$8.1K | 0.36% | 68 |
|
|
2020
Q2 | $878K | Sell |
8,941
-101
| -1% | -$8.89K | 0.43% | 53 |
|
|
2020
Q1 | $689K | Buy |
9,042
+95
| +1% | +$8.09K | 0.41% | 58 |
|
|
2019
Q4 | $792K | Buy |
8,947
+11
| +0.1% | +$913 | 0.36% | 69 |
|
|
2019
Q3 | $677K | Buy |
8,936
+709
| +9% | +$48.6K | 0.33% | 88 |
|
|
2019
Q2 | $598K | Buy |
8,227
+7
| +0.1% | +$550 | 0.3% | 95 |
|
|
2019
Q1 | $662K | Buy |
8,220
+541
| +7% | +$44.3K | 0.38% | 78 |
|
|
2018
Q4 | $708K | Buy |
7,679
+200
| +3% | +$17.6K | 0.46% | 69 |
|
|
2018
Q3 | $707K | Sell |
7,479
-1,000
| -12% | -$94.8K | 0.39% | 75 |
|
|
2018
Q2 | $786K | Sell |
8,479
-175
| -2% | -$17.1K | 0.48% | 61 |
|
|
2018
Q1 | $819K | Sell |
8,654
-102
| -1% | -$11.2K | 0.49% | 66 |
|
|
2017
Q4 | $847K | Hold |
8,756
| – | – | 0.54% | 57 |
|
|
2017
Q3 | $778K | Sell |
8,756
-298
| -3% | -$22.7K | 0.57% | 50 |
|
|
2017
Q2 | $657K | Sell |
9,054
-21
| -0.2% | -$1.41K | 0.47% | 58 |
|
|
2017
Q1 | $592K | Hold |
9,075
| – | – | 0.45% | 59 |
|
|
2016
Q4 | $568K | Hold |
9,075
| – | – | 0.45% | 65 |
|
|
2016
Q3 | $573K | Hold |
9,075
| – | – | 0.46% | 58 |
|
|
2016
Q2 | $562K | Buy |
9,075
+60
| +0.7% | +$3.66K | 0.53% | 50 |
|
|
2016
Q1 | $515K | Hold |
9,015
| – | – | 0.56% | 52 |
|
|
2015
Q4 | $534K | Sell |
9,015
-500
| -5% | -$28.8K | 0.6% | 54 |
|
|
2015
Q3 | $487K | Sell |
9,515
-300
| -3% | -$19.5K | 0.52% | 58 |
|
|
2015
Q2 | $688K | Hold |
9,815
| – | – | 0.72% | 43 |
|
|
2015
Q1 | $632K | Sell |
9,815
-300
| -3% | -$18.1K | 0.65% | 48 |
|
|
2014
Q4 | $566K | Buy |
+10,115
| New | +$638K | 0.58% | 52 |
|
Other funds holding ABBV
Diligent Investors's ABBV Position: Q2 2026 in Review
Diligent Investors increased its AbbVie (ABBV) stake by 2.4% in Q2 2026, buying an estimated $13.6K and bringing the position to 2,700 shares worth $679K. The position accounts for 0.15% of the portfolio, ranked #181.
Diligent Investors first reported a position in ABBV in Q4 2014 and has held it in 47 quarters since. The position peaked at $1.76M in Q1 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Diligent Investors held 2,700 shares of AbbVie worth $679K as of Q2 2026.
- Diligent Investors bought 63 AbbVie shares in Q2 2026, an estimated $13.6K.
- AbbVie made up 0.15% of Diligent Investors's portfolio in Q2 2026, its #181 holding.
- Diligent Investors first reported a position in AbbVie in Q4 2014 and has held it in 47 quarters since.
- Diligent Investors's AbbVie position peaked at $1.76M in Q1 2025.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Diligent Investors's 13F filing for Q2 2026, filed 24 Jul 2026.